Loading...
•
Dec 31, 2023
Disc Medicine Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Takeaways
Disc Medicine reported its Q4 and full year 2023 financial results, highlighting positive read-outs for bitopertin and DISC-0974 and advancement of DISC-3405 into the clinic. The company ended the year with approximately $360.4 million in cash and cash equivalents.
Top-line results from AURORA, the phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024
On track to deliver multiple read-outs in 2024, including updated results from phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF) 1H’24
Strengthened leadership team with the appointments of Jean Franchi as Chief Financial Officer and Pamela Stephenson as Chief Commercial Officer, and the promotion of Jonathan Yu to Chief Operating Officer
Well-capitalized, ending 2023 with approximately $360M in cash and cash equivalents, which provides runway well into 2026
Disc Medicine
Disc Medicine
Forward Guidance
Disc Medicine anticipates multiple read-outs in 2024, including AURORA data and updated results from DISC-0974 and DISC-3405 studies.